Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html
https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/
https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-initiation-of-phase-12-clinical-trial-to-study-tegavivint-in-pediatric-cancers-301419711.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-initiation-of-phase-1-clinical-trial-to-study-tegavivint-in-acute-myeloid-leukemia-301403155.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-confirms-safety-of-tegavivint-following-completion-of-enrollment-in-phase-12a-expansion-study-in-patients-with-desmoid-tumors-301267414.html